These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 26735340)

  • 1. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.
    Di Gangi IM; Mazza T; Fontana A; Copetti M; Fusilli C; Ippolito A; Mattivi F; Latiano A; Andriulli A; Vrhovsek U; Pazienza V
    Oncotarget; 2016 Feb; 7(5):5815-29. PubMed ID: 26735340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
    Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination.
    Itoi T; Sugimoto M; Umeda J; Sofuni A; Tsuchiya T; Tsuji S; Tanaka R; Tonozuka R; Honjo M; Moriyasu F; Kasuya K; Nagakawa Y; Abe Y; Takano K; Kawachi S; Shimazu M; Soga T; Tomita M; Sunamura M
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28375170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a metabolite calculator for diagnosis of pancreatic cancer.
    Choi M; Park M; Lee SH; Lee MJ; Paik YK; Jang SI; Lee DK; Lee SG; Kang CM
    Cancer Med; 2023 Aug; 12(15):15933-15944. PubMed ID: 37350558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
    He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
    Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
    Farshidfar F; Weljie AM; Kopciuk KA; Hilsden R; McGregor SE; Buie WD; MacLean A; Vogel HJ; Bathe OF
    Br J Cancer; 2016 Sep; 115(7):848-57. PubMed ID: 27560555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LC-MS/MS and SWATH based serum metabolomics enables biomarker discovery in pancreatic cancer.
    Xiong Y; Shi C; Zhong F; Liu X; Yang P
    Clin Chim Acta; 2020 Jul; 506():214-221. PubMed ID: 32243985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection.
    Ritchie SA; Akita H; Takemasa I; Eguchi H; Pastural E; Nagano H; Monden M; Doki Y; Mori M; Jin W; Sajobi TT; Jayasinghe D; Chitou B; Yamazaki Y; White T; Goodenowe DB
    BMC Cancer; 2013 Sep; 13():416. PubMed ID: 24024929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Metabolomics as a Complementary Omic Approach to Implement Risk Criteria for First-Degree Relatives of Gastric Cancer Patients.
    Corona G; Cannizzaro R; Miolo G; Caggiari L; De Zorzi M; Repetto O; Steffan A; De Re V
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metabolomic detection of lung cancer biomarkers in sputum.
    Cameron SJ; Lewis KE; Beckmann M; Allison GG; Ghosal R; Lewis PD; Mur LA
    Lung Cancer; 2016 Apr; 94():88-95. PubMed ID: 26973212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
    Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
    J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients.
    Fontana A; Copetti M; Di Gangi IM; Mazza T; Tavano F; Gioffreda D; Mattivi F; Andriulli A; Vrhovsek U; Pazienza V
    Oncotarget; 2016 Feb; 7(8):8968-78. PubMed ID: 26840268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.
    Zhang X; Xu L; Shen J; Cao B; Cheng T; Zhao T; Liu X; Zhang H
    Biochim Biophys Acta; 2013 Aug; 1832(8):1207-16. PubMed ID: 23524237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra-High Performance Liquid Chromatography-Mass Spectrometry-based Serum Metabolomics for Early Diagnosis of Refractory Tumor-induced Osteomalacia: A Case-control Study.
    Li X; Gong Y; Zhang Q; Ni X; Pang Q; Chi Y; Jiajue R; Cui L; Jiang X; Wang O; Xing X; Jiang Y; Li M; Xia W
    J Clin Endocrinol Metab; 2023 Jul; 108(8):2016-2023. PubMed ID: 36718510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A quantitative multimodal metabolomic assay for colorectal cancer.
    Farshidfar F; Kopciuk KA; Hilsden R; McGregor SE; Mazurak VC; Buie WD; MacLean A; Vogel HJ; Bathe OF
    BMC Cancer; 2018 Jan; 18(1):26. PubMed ID: 29301511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of identifying pancreatic cancer based on serum metabolomics.
    Bathe OF; Shaykhutdinov R; Kopciuk K; Weljie AM; McKay A; Sutherland FR; Dixon E; Dunse N; Sotiropoulos D; Vogel HJ
    Cancer Epidemiol Biomarkers Prev; 2011 Jan; 20(1):140-7. PubMed ID: 21098649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolomic Profiling of Plasma from Patients with Tuberculosis by Use of Untargeted Mass Spectrometry Reveals Novel Biomarkers for Diagnosis.
    Lau SK; Lee KC; Curreem SO; Chow WN; To KK; Hung IF; Ho DT; Sridhar S; Li IW; Ding VS; Koo EW; Wong CF; Tam S; Lam CW; Yuen KY; Woo PC
    J Clin Microbiol; 2015 Dec; 53(12):3750-9. PubMed ID: 26378277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic classification of pancreatic adenocarcinoma tissue using protein chip technology.
    Scarlett CJ; Smith RC; Saxby A; Nielsen A; Samra JS; Wilson SR; Baxter RC
    Gastroenterology; 2006 May; 130(6):1670-8. PubMed ID: 16697731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study.
    Ríos Peces S; Díaz Navarro C; Márquez López C; Caba O; Jiménez-Luna C; Melguizo C; Prados JC; Genilloud O; Vicente Pérez F; Pérez Del Palacio J
    SLAS Discov; 2017 Apr; 22(4):348-359. PubMed ID: 27655283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer.
    Ikeda A; Nishiumi S; Shinohara M; Yoshie T; Hatano N; Okuno T; Bamba T; Fukusaki E; Takenawa T; Azuma T; Yoshida M
    Biomed Chromatogr; 2012 May; 26(5):548-58. PubMed ID: 21773981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.